Momentum

Relative Strength (%)
1m-8.46%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-50.02%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for CELC

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Celcuity EPS forecast chart

Profile Summary

Celcuity, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering cancer sub-types molecular-based approaches through developing companion diagnostic tests (CDx) and therapeutic (Rx). The Company's product pipeline includes CELsignia platform and Gedatolisib. The CELsignia diagnostic platform is used to analyze live patient tumor cells to identify the specific abnormal cellular process driving a patients cancer and the targeted therapy. The CELsignia platform provides traditional molecular diagnostics, which includes snapshot of the genetic mutations present in a patients tumor because they analyze cell fragments and molecular diagnostics can estimate the patients potential drug response based on a statistical analysis of the drugs clinical trial result. Its other product candidate includes Gedatolisib, is a small molecule dual inhibitor, administered intravenously, that targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR).

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
September 15th, 2017
Public Since
September 20th, 2017
No. of Shareholders
49
No. of Employees
30
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
14,913,889

CELC Share Price Performance

Latest News for CELC

Upcoming Events for CELC

Q4 2021 Celcuity Inc Earnings Release

Q1 2022 Celcuity Inc Earnings Release

Celcuity Inc Annual Shareholders Meeting

Similar to CELC

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of 9 Meters Biopharma logo

9 Meters Biopharma

us flag iconNASDAQ Capital Market

Picture of Aadi Bioscience logo

Aadi Bioscience

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email